Cell surface markers of cancer stem cells: Diagnostic macromolecules and targets for drug delivery

Drug Delivery and Translational Research

Volumn 3, Issue 2, 2013, Pages 121-142

  Andrews, Timothy E ^a   Wang, Dan ^a   Harki, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anticancer agents; Cancer stem cell markers; Cancer stem cells; Cell surface proteins; Disease relapse; Flow cytometry

Indexed keywords

ADECATUMUMAB; BESTATIN; CATUMAXOMAB; CD123 ANTIGEN; CD133 ANTIGEN; CD33 ANTIGEN; CD44V ANTIGEN; CELL SURFACE MARKER; DOCETAXEL; EDRECOLOMAB; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; MT 110; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER STEM CELL; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG DELIVERY SYSTEM; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; MACROMOLECULE; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER;

EID: 84874793651     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0075-1     Document Type: Review

References (232)

1. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol. 2007; 19: 61-4.
2. Behbod F, Rosen JM. Will cancer stem cells provide new therapeutic targets? Carcinogenesis. 2005; 26: 703-11.
3. Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112: 4793-807.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-11.
5. Saini V, Shoemaker RH. Potential for therapeutic targeting of tumor stem cells. Cancer Sci. 2010; 101: 16-21.
6. Wang JCY. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell. 2007; 1: 497-501.
7. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol-Mech. 2007; 2: 175-89.
8. Zhou BBS, Zhang HY, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009; 8: 806-23.
9. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-7.
10. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-cortes J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature. 1994; 367: 645-8.
11. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, et al. Clonal development, stem-cell differentiation, and clinical remission in acute nonlymphocytic leukemia. New Engl J Med. 1987; 317: 468-73.
12. Griffin JD, Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood. 1986; 68: 1185-95.
13. McCulloch EA. Stem cells in normal and leukemic hematopoiesis (Henry Stratton Lecture). Blood. 1983; 62: 1-13.
14. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res. 2011; 17: 4936-41.
15. Sehl M, Zhou H, Sinsheimer JS, Lange KL. Extinction models for cancer stem cell therapy. Math Biosci. 2011; 234: 132-46.
16. Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev Rep. 2011; 7: 119-29.
17. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012; 83: 1084-103.
18. American Cancer Society. Cancer facts & figures 2011. ACS. 2011.
19. Guzman ML, Rossi RM, Karnischky L, Li XJ, Peterson DR, Howard DS, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005; 105: 4163-9.
20. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12: 1167-74.
21. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010; 28: 275-80.
22. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 2001; 344: 1031-7.
23. Kantarjian H, Talpaz M, O'Brien SS, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103: 2873-8.
24. Nicholson E, Holyoake T. The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma. 2009; 9: S376-81.
25. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99: 319-25.
26. Zoeller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011; 11: 254-67.
27. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med-Jmm. 2011; 89: 95-107.
28. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65: 10946-51.
29. Clayton S, Mousa SA. Therapeutics formulated to target cancer stem cells: is it in our future? Cancer Cell Int. 2011; 11: 7.
30. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med. 2008; 14: 450-60.
31. Liu H-G, Chen C, Yang H, Pan Y-F, Zhang X-H. Cancer stem cell subsets and their relationships. J Transl Med. 2011; 9: 50.
32. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8: 755-68.
33. Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem. 2009; 108: 1031-8.
34. Alison MR, Lim SML, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011; 223: 147-61.
35. Jordan CT. Cancer sten cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004; 16: 708-12.
36. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
37. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-36.
38. Testa U. Leukemia stem cells. Ann Hematol. 2011; 90: 245-71.
39. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997; 89: 3104-12.
40. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood. 1998; 92: 4325-35.
41. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD 117). Exp Hematol. 2000; 28: 660-71.
42. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14: 1777-84.
43. Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, et al. Detection of molecular targets on the surface of CD34+/CD38-stem cells in various myeloid malignancies. Leukemia Lymphoma. 2006; 47: 207-22.
44. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986; 67: 1048-53.
45. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, et al. Expression of the target receptor CD33 in CD34(+)/CD38(-)/CD123(+) AML stem cells. Eur J Clin Invest. 2007; 37: 73-82.
46. de Figueiredo-Pontes LL, Pintao M-CT, Oliveira LCO, Dalmazzo LFF, Jacomo RH, Garcia AB, et al. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytom Part B-Clin Cy. 2008; 74B: 163-8.
47. van Rhenen A, van Dongen GAMS, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110: 2659-66.
48. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007; 104: 11008-13.
49. Bendall LJ, Bradstock KF, Gottlieb DJ. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34(+) cells. Leukemia. 2000; 14: 1239-46.
50. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010; 2: 17ra9.
51. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138: 286-99.
52. - marrow compartment in children with acute lymphoblastic leukemia. Leukemia. 1997; 11: 1508-15.
53. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood. 2000; 95: 1007-13.
54. Advani AS, Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leukemia Res. 2002; 26: 713-20.
55. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Rev Clin Exp Hematol. 2002; 6: 142-60.
56. Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005; 11: 630-7.
57. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1: 133-43.
58. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood. 2004; 104: 2919-25.
59. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood. 2007; 109: 674-82.
60. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood. 2009; 113: 3287-96.
61. Nishida H, Yamazaki H, Yamada T, Iwata S, Dang NH, Inukai T, et al. CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. Biochem Bioph Res Co. 2009; 382: 57-62.
62. Yamazaki H, Nishida H, Iwata S, Dang NH, Morimoto C. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem Bioph Res Co. 2009; 383: 172-7.
63. Holyoake T, Jiang XY, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999; 94: 2056-64.
64. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics. CA Cancer J Clin. 2011; 61: 409-18.
65. Takahashi R, Takeshita F, Fujiwara T, Ono M, Ochiya T. Cancer stem cells in breast cancer. Cancers. 2011; 3: 1311-28.
66. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983-8.
67. + breast cancer-initiating cells to radiation. J Natl Cancer I. 2006; 98: 1777-85.
68. Buess M, Rajski M, Vogel-Durrer BML, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia. 2009; 11: 987-1002.
69. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8: 59.
70. Donnelly DS, Zelterman D, Sharkis S, Krause DS. Functional activity of murine CD34(+) and CD34(-) hematopoietic stem cell populations. Exp Hematol. 1999; 27: 788-96.
71. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010; 176: 2131-8.
72. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells. 2008; 26: 364-71.
73. + cells with cancer stem cell characteristics. Breast Cancer Res. 2008; 10: 10.
74. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011; 102: 1107-11.
75. Liu Q, Li J-g, Zheng X-y, Jin F, Dong H-t. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chinese Med J-Peking. 2009; 122: 2763-9.
76. Lin W-M, Karsten U, Goletz S, Cheng R-C, Cao Y. Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells. Vichows Arch. 2010; 456: 403-9.
77. Lin W-M, Karsten U, Goletz S, Cheng R-C, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol. 2011; 92: 97-105.
78. Vassilopoulos A, Wang R-H, Petrovas C, Ambrozak D, Koup R, Deng C-X. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci. 2008; 4: 133-42.
79. Shipitsin M, Campbell LL, Argani P, Werernowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11: 259-73.
80. Dalerba P, Dylla SJ, Park I-K, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007; 104: 10158-63.
81. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106-10.
82. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-5.
83. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008; 118: 2111-20.
84. Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008; 14: 6751-60.
85. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009; 27: 844-50.
86. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Brit J Cancer. 2010; 103: 382-90.
87. Vermeulen L, Todaro M, Mello FdS, Sprick MR, Kemper K, Alea MP, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA. 2008; 105: 13427-32.
88. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Brit J Surg. 2011; 98: 552-7.
89. Ma S, Chan K-W, Hu L, Lee TK-W, Wo JY-H, Ng I-L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132: 2542-56.
90. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010; 126: 2067-78.
91. Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, et al. Characterization of the epithelial cell adhesion molecule (EpCAM) plus cell population in hepatocellular carcinoma cell lines. Cancer Sci. 2010; 101: 2145-55.
92. Yamashita T, Ji JF, Budhu A, Forgues M, Yang W, Wang H-Y, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136: 1012-24.
93. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010; 120: 3326-39.
94. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell. 2008; 13: 153-66.
95. Polakis P. Wnt signaling and cancer. Gene Dev. 2000; 14: 1837-51.
96. Yang W, Yan H-X, Chen L, Liu Q, He Y-Q, Yu L-X, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008; 68: 4287-95.
97. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
98. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030-7.
99. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-23.
100. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
101. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005; 65: 9328-37.
102. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007; 43: 935-46.
103. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006; 126: 142-53.
104. Fusi A, Reichelt U, Busse A, Ochsenreither S, Rietz A, Maisel M, et al. Expression of the stem cell markers Nestin and CD133 on circulating melanoma cells. J Invest Dermatol. 2011; 131: 487-94.
105. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. 2009; 31: 1038-49.
106. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008; 451: 345-9.
107. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology. 2001; 3: 152-8.
108. Khalatbari MR, Hamidi M, Moharamzad Y. Glioblastoma multiforme with very rapid growth and long-term survival in children: report of two cases and review of the literature. Child Nerv Syst. 2011; 27: 1347-52.
109. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008; 26: 2839-45.
110. Binello E, Germano IM. Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci. 2011; 102: 1958-66.
111. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63: 5821-8.
112. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396-401.
113. Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol. 2010; 20: 211-21.
114. - tumor-initiating cells in adult human gliomas. Neurosurgery. 2008; 62: 505-14.
115. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008; 122: 761-8.
116. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008; 68: 6043-8.
117. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006; 66: 7843-8.
118. Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009; 4: 440-52.
119. Read T-A, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 2009; 15: 135-47.
120. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275-84.
121. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2007; 15: 504-14.
122. Dinney CPN, McConkey DJ, Millikan RE, Wu XF, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell. 2004; 6: 111-6.
123. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidem Biomar. 2010; 19: 327-37.
124. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Nat Acad Sci. 2009; 106: 14016-21.
125. + subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008; 26: 725-33.
126. Ning ZF, Huang YJ, Lin TX, Zhou YX, Jiang C, Xu KW, et al. Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res. 2009; 37: 621-30.
127. Oates JE, Grey BR, Addla SK, Samuel JD, Hart CA, Ramani VAC, et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev. 2009; 18: 1515-21.
128. Bostwick DG, Eble JN. Urological surgical pathology. 2nd ed. New York, NY. Mosby; 2007.
129. high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009; 69: 8555-62.
130. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011; 60: 279-90.
131. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, et al. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA. 1997; 94: 10705-10.
132. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006; 25: 1696-708.
133. + cell population is enriched in tumor-initiating cells. Cancer Res. 2007; 67: 6796-805.
134. Suzuki A, Nakano T, Mak TW, Sasaki T. Portrait of PTEN: messages from mutant mice. Cancer Sci. 2008; 99: 209-13.
135. Zhang S, Balch C, Chan MW, Lai H-C, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68: 4311-20.
136. Choi YP, Shim HS, Gao M-Q, Kang S, Cho NH. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett. 2011; 307: 62-71.
137. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2008; 18: 506-14.
138. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009; 27: 2875-83.
139. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010; 29: 2672-80.
140. Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA. 2010; 107: 18874-9.
141. Gupta PB, Onder TT, Jiang GZ, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138: 645-59.
142. Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/prominin-1. Int J Biochem Cell B. 2005; 37: 715-9.
143. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster Jr JR, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS One. 2008; 3.
144. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA. 1997; 94: 12425-30.
145. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 2008; 26: 3008-17.
146. Wu YJ, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009; 18: 1127-34.
147. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med-Jmm. 2008; 86: 1025-32.
148. Swaminathan SK, Olin MR, Forster CL, Cruz KSS, Panyam J, Ohlfest JR. Identification of a novel monoclonal antibody recognizing CD133. J Immunol Methods. 2010; 361: 110-5.
149. Wang C-H, Chiou S-H, Chou C-P, Chen Y-C, Huang Y-J, Peng C-A. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomed-Nanotechnol. 2011; 7: 69-79.
150. Bourseau-Guilmain E, Bejaud J, Griveau A, Lautram N, Hindre F, Weyland M, et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm. 2012; 423: 93-101.
151. van der Gun BTF, Melchers LJ, Ruiters MHJ, de Leij LFMH, McLaughlin PMJ, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010; 31: 1913-21.
152. Winter MJ, Nagelkerken B, Mertens AEE, Rees-Bakker HAM, Briaire-de Bruijn IH, Litvinov SV. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res. 2003; 285: 50-8.
153. Litvinov SV, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO. Ep-CAM-a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994; 125: 437-46.
154. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Brit J Cancer. 2007; 97: 315-21.
155. Chelius D, Ruf P, Gruber P, Ploscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MABS. 2010; 2: 309-19.
156. Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jager M. Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal phase II/III study. J Clin Oncol. 2009; 27.
157. Jager M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). Cancer Res. 2012; 72: 24-32.
158. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010; 36: 458-67.
159. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006; 43: 1129-43.
160. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009; 11: 22-30.
161. Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res. 2008; 68: 143-51.
162. Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Ruttinger D, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One. 2010; 5.
163. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuese R, Schlereth B, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009; 214: 441-53.
164. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med-Jmm. 1999; 77: 699-712.
165. Riethmuller G, Schneidergadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Randomized trial of monoclonal-antibody for adjuvant therapy of resected Dukes-C colorectal-carcinoma. Lancet. 1994; 343: 1177-83.
166. Braun S, Hepp F, Kentenich CRM, Janni W, Pantel K, Riethmuller G, et al. Monoclonal antibody therapy with Edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res. 1999; 5: 3999-4004.
167. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer. 2002; 100: 101-10.
168. Hartung G, Hofheinz RD, Dencausse Y, Sturm J, Kopp-Schneider A, Dietrich G, et al. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie. 2005; 28: 347-50.
169. Schmidt M, Ruttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol. 2012.
170. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983; 304: 30-4.
171. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principle cell-surface receptor for hyaluronate. Cell. 1990; 61: 1303-13.
172. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph-node homing is a member of the cartilage link protein family. Cell. 1989; 56: 1057-62.
173. Teriete P, Banerji S, Noble M, Blundell CD, Wright AJ, Pickford AR, et al. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Mol Cell. 2004; 13: 483-96.
174. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004; 95: 930-5.
175. Vigetti D, Viola M, Karousou E, Rizzi M, Moretto P, Genasetti A, et al. Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging. J Biol Chem. 2008; 283: 4448-58.
176. Cheng CH, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol. 2006; 26: 362-70.
177. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic-acid binding-sites in the extracellular domain of Cd44. J Cell Biol. 1993; 122: 257-64.
178. Ishii S, Ford R, Thomas P, Nachman A, Steele G, Jessup JM. Cd44 participates in the adhesion of human colorectal-carcinoma cells to laminin and type-IV collagen. Surg Oncol. 1993; 2: 255-64.
179. Jalkanen S, Jalkanen M. Lymphocyte Cd44 binds the Cooh-terminal heparin-binding domain of fibronectin. J Cell Biol. 1992; 116: 817-25.
180. Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Ann Rev Biomed Eng. 2009; 11: 177-202.
181. Toyamasorimachi N, Miyasaka M. A novel ligand for Cd44 is sulfated proteoglycan. Int Immunol. 1994; 6: 655-60.
182. Liu DC, Sy MS. Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. J Immunol. 1997; 159: 2702-11.
183. Oliferenko S, Paiha K, Harder T, Gerke V, Schwarzler C, Schwarz H, et al. Analysis of CD44-containing lipid rafts: recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol. 1999; 146: 843-54.
184. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Bio. 2010; 11: 276-87.
185. Siegelman MH, Stanescu D, Estess P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J Clin Invest. 2000; 105: 683-91.
186. Williams DA, Cancelas JA. Leukaemia-niche retreats for stem cells. Nature. 2006; 444: 827-8.
187. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008; 14: 818-29.
188. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004; 4: 528-39.
189. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Bi. 2007; 23: 675-99.
190. Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program. 2005: 143-50.
191. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006; 6: 93-106.
192. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005; 106: 1901-10.
193. Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Brit J Cancer. 2009; 100: 918-22.
194. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999; 29: 3440-9.
195. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem. 1999; 274: 11505-12.
196. Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, et al. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci U S A. 2001; 98: 5764-9.
197. Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol. 2006; 133: 141-51.
198. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003; 3: 386-90.
199. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002; 13: 47-58.
200. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002; 13: 40-6.
201. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005; 19: 176-82.
202. http://www. fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458. htm.
203. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012.
204. Furness SGB, McNagny K. Beyond mere markers-functions for CD34 family of sialomucins in hematopoiesis. Immunol Res. 2006; 34: 13-32.
205. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. 3. A hematopoietic progenitor-cell surface-antigen defined by a monoclonal-antibody raised against Kg-1a cells. J Immunol. 1984; 133: 157-65.
206. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter G, Buckner CD, et al. Antigen Cd34+ marrow-cells engraft lethally irradiated baboons. J Clin Invest. 1988; 81: 951-5.
207. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci. 2008; 121: 3683-92.
208. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood. 1996; 87: 1-13.
209. Healy L, May G, Gale K, Grosveld F, Greaves M, Enver T. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc Natl Acad Sci USA. 1995; 92: 12240-4.
210. Baumhueter S, Singer MS, Henzel W, Hemmerich S, Renz M, Rosen SD, et al. Binding of l-selectin to the vascular sialomucin CD34. Science. 1993; 262: 436-8.
211. Krause DS, Ito T, Fackler MJ, Smith OM, Collector MI, Sharkis SJ, et al. Characterization of murine CD34, a marker for hematopoietic progenitor and stem-cells. Blood. 1994; 84: 691-701.
212. Tan PC, Furness SGB, Merkens H, Lin SJ, McCoy ML, Roskelley CD, et al. Na+/H + exchanger regulatory factor-1 is a hematopoietic ligand for a subset of the CD34 family of stem cell surface proteins. Stem Cells. 2006; 24: 1150-61.
213. Fackler MJ, Krause DS, Smith OM, Civin CI, May WS. Full-length but not truncated Cd34 inhibits hematopoietic-cell differentiation of M1 cells. Blood. 1995; 85: 3040-7.
214. Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, et al. Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006; 15: 305-13.
215. Kawanobe T, Kogure S, Nakamura S, Sato M, Katayama K, Mitsuhashi J, et al. Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem Bioph Res Co. 2012; 418: 736-41.
216. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005; 65: 4320-33.
217. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008; 451: 345-9.
218. Wickstrom M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011; 102: 501-8.
219. Luan YP, Xu WF. The structure and main functions of aminopeptidase N. Curr Med Chem. 2007; 14: 639-47.
220. Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T. Bestatin, an inhibitor of aminopeptidase-B, produced by actinomycetes. J Antibiot. 1976; 29: 97-9.
221. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res. 1986; 46: 4505-10.
222. Mathe G. Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function. Biomed Pharmacother. 1991; 45: 49-54.
223. Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 1999; 13: 729-34.
224. Ezawa K, Minato K, Dobashi K. Induction of apoptosis by ubenimex (Bestatin(R)) in human non-small-cell lung cancer cell lines. Biomed Pharmacother. 1996; 50: 283-9.
225. Thunnissen MMGM, Nordlund P, Haeggstrom JZ. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol. 2001; 8: 131-5.
226. Tholander F, Rudberg P, Thunnissen M, Haeggstrom JZ. Leukotriene A4 hydrolase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. Prostag Oth Lipid M. 2006; 79: 157.
227. Fromm JR. Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma. Cytom Part B-Clin Cy. 2011; 80B: 91-9.
228. Jin LQ, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5: 31-42.
229. Lindberg FP, Gresham HD, Schwarz E, Brown EJ. Molecular-cloning of integrin-associated protein-an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha-nu-beta-3-dependent ligand-binding. J Cell Biol. 1993; 123: 485-96.
230. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001; 11: 130-5.
231. Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell. 2008; 31: 266-77.
232. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011; 30: 1009-19.